You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 9,427,477

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,427,477

Title:	Cancer treatments
Abstract:	This document provides methods and materials related to treating cancer (e.g., skin cancer). For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., Abraxane.RTM./anti-VEGF polypeptide antibody complexes) to treat cancer (e.g., skin cancer) are provided.
Inventor(s):	Markovic; Svetomir N. (Rochester, MN), Nevala; Wendy K. (Rochester, MN)
Assignee:	Mayo Foundation for Medical Education and Research (Rochester, MN)
Application Number:	14/116,619
Patent Claims:	1. A method for treating cancer in a mammal, which method comprises: (a) obtaining a dry composition of preformed nanoparticle complexes comprising albumin-bound paclitaxel and bevacizumab at a ratio of up to 5:1; (b) forming an aqueous composition of said dry composition, said aqueous composition being suitable for injection into a mammal having cancer, and (c) administering to said mammal an effective amount of said aqueous composition wherein said administration treats said cancer and further wherein said preformed nanoparticle complexes retain antibody mediated target binding specificity. 2. The method of claim 1, wherein said mammal is a human. 3. The method of claim 1, wherein said cancer is skin cancer. 4. The method of claim 3, wherein said skin cancer is stage IV melanoma. 5. The method of claim 1, wherein said preformed nanoparticle complexes comprise an alkylating agent. 6. The method of claim 1, wherein said administration of said injectable composition is by intravenous drip.

Details for Patent 9,427,477

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004	⤷ Try a Trial	2031-05-09
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.